The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study

Глезер, М. Г.

doi:10.1007/s12325-018-0674-4

Cited by 5 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of guidelines and those of the European Society of Cardiology (ESC), consider sublingual or shortacting nitroglycerine, β-blockers, and CCBs as first-choice therapy, whilst the other more recent drugs (ivabradine, nicorandil, ranolazine, and trimetazidine) are restricted for patients who have contraindications to the first-choice drugs, patients who fail to tolerate them, or patients who remain asymptomatic. [14][15][16][17] For patients with stable angina whose condition is not controlled by monotherapy with nitrates, β-blockers, or CCBs are often used in combination with other drugs. There may be adverse effects from or contraindications to the use of combinations.…”

Section: Discussionmentioning

confidence: 99%

A nationwide questionnaire-based survey on practice patterns and management of chronic stable angina with a controlled release formulation of trimetazidine

Balachandran¹,

Jaganathan²,

Jhala³

et al. 2021

Int J Adv Med

View full text Add to dashboard Cite

Background: There is lack of real-world evidence on various aspects of chronic stable angina (CSA). Hence, a questionnaire-based survey was conducted to garner real-world data about the prevalence of CSA among Indian patients; the associated comorbidities among these patients; management practices for CSA in India; and factors affecting compliance in patients with CSA with a special focus on day and night pack for trimetazidine controlled release (CR) 35 mg BD tablets.Methods: In all, 100 health care practitioners (HCPs) who each observed 15 patients with CSA in their clinical practice participated in this quantitative, cross-sectional, questionnaire-based study. The data were collected using a structured questionnaire with 30 questions grouped into 5 sections. Data were analyzed using percentages.Results: The results from the survey showed that 52.7% HCPs had observed 31-50% of angina patients with diabetes mellitus as comorbidity. As per the questionnaire survey, 77.4% HCPs preferred trimetazidine as a second-line agent when an angina patient was not responding to beta-blockers, calcium channel blockers (CCBs), and nitrates. Furthermore, 30.1% of HCPs preferred trimetazidine CR 35 mg BD as it improved exercise tolerance as well. Results from the survey reported that 65.6% HCPs agreed with the statement that day and night packs of trimetazidine tablets help in improving patient compliance and adherence to therapy.Conclusions: Trimetazidine CR 35 mg BD appears to have a safety profile suitable for various conditions and for patients with multiple comorbidities. Trimetazidine day and night packs of tablets help in improving patient compliance and adherence to therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A nationwide questionnaire-based survey on practice patterns and management of chronic stable angina with a controlled release formulation of trimetazidine

Balachandran¹,

Jaganathan²,

Jhala³

et al. 2021

Int J Adv Med

View full text Add to dashboard Cite

show abstract

“…Rate and increase in the efficiency of utilizing oxygen during myocardial hypoxia; (b) reduce intracellular acidosis and inorganic phosphorus accumulation during cardiac ischemia; (c) reduce intracellular sodium and calcium accumulation, and reduce The cell damage caused by it protects mitochondrial function and energy metabolism; (d) inhibits the accumulation of white blood cells to the ischemic site and reduces tissue damage. 19–22 TMZ protects cardiomyocytes from ischemia and hypoxia through these pathways, and achieves anti ischemia effect at the cellular level. TMZ has been shown to have strong antioxidant effect in myocardium, kidney, and liver of rats with ischemia-reperfusion injury.…”

Section: Discussionmentioning

confidence: 99%

Preventive effect of trimetazidine on contrast-induced nephropathy undergoing percutaneous coronary intervention in elderly moderate and high risk diabetics stratified by mehran score

et al. 2020

View full text Add to dashboard Cite

Background: The aim of this research was to use the Mehran risk score to classify elderly diabetics with coronary heart disease to assess the preventive effect of trimetazidine on contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) in different risk population. Methods: An uncompromised of 760 elderly diabetics that went through PCI were included in this research. The patients were first divided into three groups in the light of MRS: low-risk, moderate-risk, and high-risk group, then randomized into trimetazidine group and the control group respectively. The first endpoint was the amount of CIN, which is described as a rise in serum creatinine levels by ⩾44.2 μmol/L or ⩾25% ratio within 48 or 72 hours after medication. Second endpoint included differences in creatinine clearance rate (CrCl), blood urea nitrogen (BUN), serum creatinine (Scr), cystatin-C (Cys-C), and the incidence of major adverse events after administration. Results: In the three groups, the incidence of CIN in trimetazidine and control group was 5.0% versus 4.9%(χ2 = 0.005, p > 0.05), 8.0% versus 18.0% (χ2 = 7.685, p < 0.05), 10.4% versus 27.1% (χ2 = 4.376, p < 0.05), respectively. The multivariable logistic regression result demonstrated that trimetazidine intervention was a profitable element of CIN in moderate and high-risk groups (OR = 0.294, 95% CI 0.094-0.920, p = 0.035). Conclusion: Our study confirmed that trimetazidine can be considered for preventive treatment of CIN occurrence in elderly diabetics with moderate and high-risk population, while there is no obvious advantage compared with hydration therapy in low-risk patients.

show abstract

“…The mechanism of action of TMZ differs from that of other antianginal drugs. It targets directly myocardial cells, optimizing cellular energetics particularly under ischemic conditions [ 5 ], which makes it a valuable antianginal therapy regardless of the background medications [ 11 ]. The antianginal efficacy of TMZ has been shown in controlled trials in patients with stable angina treated with TMZ in monotherapy or as a part of combination therapy [ 12 – 16 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Long-acting Trimetazidine in Different Clinical Situations in Patients with Stable Angina Pectoris: Findings from ODA Trial

2019

View full text Add to dashboard Cite

Introduction Trimetazidine (TMZ) has been shown to be efficacious for angina treatment. The TMZ 80-mg formulation allows one-daily (od) dosage, which could improve symptom control and adherence. Methods The 3-month, observational, multicenter, prospective ODA (antianginal effectiveness and tolerability of trimetazidine modified release 80 mg Once Daily in stable Angina patients in real-world practice) study assessed TMZ 80 mg od effectiveness in stable angina patients with persistent symptoms despite therapy. Two clinical situations were compared: patients who initiated treatment with TMZ 80 mg od (initiation group) and patients who were previously treated with TMZ 20 mg thrice daily (tid) or TMZ 35 mg MR twice daily (bid) and switched to TMZ 80 mg od (switch group). Number of angina attacks, short-acting nitrate (SAN) consumption, self-reported patient daily activity, Canadian Cardiovascular Society (CCS) class, adherence to antianginal therapy, overall efficacy and tolerability were assessed. Results A significant decrease in weekly number of angina attacks was observed for both the initiation group ( n = 1841 patients) from 4.8 ± 3.5 at baseline to 0.9 ± 1.4 at 3 months (M3) ( P < 0.001), and the switch group ( n = 1216 patients) from 4.4 ± 1.3 at baseline to 0.9 ± 1.3 at M3 ( P < 0.001). Significant reduction in SAN consumption and improvement in CCS class were observed for both groups. Adherence to antianginal therapy improved in both groups at 1 month (M1) and M3. Overall effectiveness of TMZ 80 mg od was rated by physicians as “very good” (68% initiation group, 70% switch group), “good” (31% initiation group, 29% switch group), “moderate” (1%, both groups) or “poor” (< 1%, both groups). Overall tolerability of TMZ 80 mg od was rated by physicians as “very good” (75%), “good” (25%) or “moderate” (< 1%) in both groups. Conclusions TMZ 80 mg od, in association with other antianginal therapy, effectively reduced angina attacks and SAN consumption and improved physical activity and adherence to antianginal therapy both in patients initiating TMZ treatment and those switching from a bid or tid formulation. Trial Registration ISRCTN registry Identifier, ISRCTN97780949. Funding Servier. Plain Language Summary Plain language summary available for this article. Electronic supplementary material The online version of this article (10.1007/s40119-019-0128-3) contains supplementary material, which is available to authorized users.

show abstract

The Effectiveness of Trimetazidine Treatment in Patients with Stable Angina Pectoris of Various Durations: Results from the CHOICE-2 Study

Abstract: ISRCTN identifier ISRCTN65209863.

Cited by 5 publications

References 14 publications

A nationwide questionnaire-based survey on practice patterns and management of chronic stable angina with a controlled release formulation of trimetazidine

A nationwide questionnaire-based survey on practice patterns and management of chronic stable angina with a controlled release formulation of trimetazidine

Preventive effect of trimetazidine on contrast-induced nephropathy undergoing percutaneous coronary intervention in elderly moderate and high risk diabetics stratified by mehran score

Effectiveness of Long-acting Trimetazidine in Different Clinical Situations in Patients with Stable Angina Pectoris: Findings from ODA Trial

Contact Info

Product

Resources

About